GOLDENWELL BIOTECH, INC. (GWLL) Form 8-K — May 26, 2026

Goldenwell Biotech, Inc. announced that its financial statements for the first three quarters of 2025 can no longer be relied upon due to material accounting errors identified by its auditor. The company failed to properly accrue $9,840 in legal fees and misapplied revenue recognition criteria for a service contract, requiring a restatement of its Q1, Q2, and Q3 2025 10-Q filings. The auditor, Michael Gillespie & Associates, PLLC, confirmed the errors, noting that legal expenses should have been recorded in the quarters services were performed rather than when the invoice was received.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.